Memorial Sloan Kettering Cancer Center’s Royalty Pharma RPRX Stock Holding History

Memorial Sloan Kettering Cancer Center’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,128,255	Closed	-$44M	–	6
2022 Q1	$44M	Sell	1,128,255 -1,552,389	-58%	-$61M	50.9%	1
2021 Q4	$107M	Hold	2,680,644	–	–	67.12%	1
2021 Q3	$96.9M	Hold	2,680,644	–	–	60.36%	1
2021 Q2	$110M	Hold	2,680,644	–	–	71.84%	1
2021 Q1	$117M	Sell	2,680,644 -885,243	-25%	-$42M	72.07%	1
2020 Q4	$178M	Buy	+3,565,887	New	+$151M	75.56%	1

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Memorial Sloan Kettering Cancer Center's RPRX Position: Q2 2022 in Review

Memorial Sloan Kettering Cancer Center sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 1,128,255 shares — an estimated $44M sold.

Memorial Sloan Kettering Cancer Center first reported a position in RPRX in Q4 2020 and held it in 6 quarters. The position peaked at $178M in Q4 2020. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Memorial Sloan Kettering Cancer Center reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Memorial Sloan Kettering Cancer Center sold 1,128,255 Royalty Pharma shares in Q2 2022, an estimated $44M.
Memorial Sloan Kettering Cancer Center first reported a position in Royalty Pharma in Q4 2020 and held it in 6 quarters.
Memorial Sloan Kettering Cancer Center's Royalty Pharma position peaked at $178M in Q4 2020.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Memorial Sloan Kettering Cancer Center's 13F filing for Q2 2022, filed 15 Aug 2022.